Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Summaries for Patients |16 May 2000

Mechanisms of Thrombotic Thrombocytopenic Purpura (TTP), a Complication Associated with the Drug Ticlopidine

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
  • The summary below is from the full report titled “Antibody Inhibitors to von Willebrand Factor Metalloproteinase and Increased Binding of von Willebrand Factor to Platelets in Ticlopidine-Associated Thrombotic Thrombocytopenic Purpura.” It is in the 16 May 2000 issue of Annals of Internal Medicine (volume 132, pages 794-799). The authors are H.-M. Tsai, L. Rice, R. Sarode, T.W. Chow, and J.L. Moake.


Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
  • FULL ARTICLE
    • What is the problem and what is known about it so far?
    • Why did the researchers do this particular study?
    • Who was studied?
    • How was the study done?
    • What did the researchers find?
    • What were the limitations of the study?
    • What are the implications of the study?
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link

What is the problem and what is known about it so far?

Ticlopidine is a drug that acts on platelets, the tiny cells in the bloodstream that help blood to clot. Ticlopidine is therefore sometimes used to reduce the risk for strokes by preventing clotting in patients whose arteries leading to the brain are greatly narrowed. It is also used to prevent clots from blocking cardiac stents (tunnel-like devices that are sometimes used to open narrowed blood vessels in the heart), thus cutting down the risk of heart attacks. Thrombotic thrombocytopenic purpura (TTP) is a medical condition that can occur on its own, but it has also been reported as a side effect of ticlopidine. TTP, a potentially serious and sometimes fatal illness, includes kidney problems, fever, bleeding, confusion, and seizures. It is not known how ticlopidine leads to TTP. However, in cases of TTP not related to a drug, a substance found normally in the bloodstream that helps blood to clot (called von Willebrand factor) is involved.

Why did the researchers do this particular study?

To see whether von Willebrand factor is one of the factors that helps to cause TTP when this condition occurs as a harmful side effect of ticlopidine therapy.

Who was studied?

Seven patients who developed TTP 2 to 7 weeks after they began taking ticlopidine. For comparison, the researchers also studied patients in two control groups: 7 patients who had taken ticlopidine for 3 to 5 weeks but had not developed TTP, and 10 hospitalized patients selected at random.

How was the study done?

The researchers measured von Willebrand factor and tested its activity in blood samples of the patients with TTP and the control patients. The patients who developed TTP received standard treatment for this condition, which included stopping the ticlopidine therapy.

What did the researchers find?

The patients with ticlopidine-associated TTP had abnormalities of von Willebrand factor that were not present in the control patients. These abnormalities were similar to the abnormalities previous researchers have found in patients with the form of TTP not related to a drug. All of the TTP patients recovered.

What were the limitations of the study?

The number of patients in this study was very small, and these patients may not be typical of all patients with drug-related TTP. It will be important to do additional studies of patients with ticlopidine-related TTP in order to understand more fully why this complication develops in some patients taking the drug but not in others.

What are the implications of the study?

Problems with von Willebrand factor appear to occur in the type of TTP associated with ticlopidine, just as they do when TTP is not related to drugs.

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

Not Available
Citations
Citation

Mechanisms of Thrombotic Thrombocytopenic Purpura (TTP), a Complication Associated with the Drug Ticlopidine. Ann Intern Med. 2000;132:794. doi: https://doi.org/10.7326/0003-4819-132-10-200005160-00039

Download citation file:

  • Ris (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2019

×
Permissions

Published: Ann Intern Med. 2000;132(10):794.

DOI: 10.7326/0003-4819-132-10-200005160-00039

©
2000 American College of Physicians
0 Citations

See Also

Antibody Inhibitors to von Willebrand Factor Metalloproteinase and Increased Binding of von Willebrand Factor to Platelets in Ticlopidine-Associated Thrombotic Thrombocytopenic Purpura
View MoreView Less

Related Articles

Thrombotic Thrombocytopenic Purpura Associated with Ticlopidine: A Review of 60 Cases
Annals of Internal Medicine; 128 (7): 541-544
Antibody Inhibitors to von Willebrand Factor Metalloproteinase and Increased Binding of von Willebrand Factor to Platelets in Ticlopidine-Associated Thrombotic Thrombocytopenic Purpura
Annals of Internal Medicine; 132 (10): 794-799
Remission of Chronic Thrombotic Thrombocytopenic Purpura after Treatment with Cyclophosphamide and Rituximab
Annals of Internal Medicine; 138 (2): 105-108
Thrombotic Thrombocytopenic Purpura: From the Bench to the Bedside, but Not Yet to the Community
Annals of Internal Medicine; 138 (2): 152-153
View MoreView Less

Related Topics

Coagulopathies
Hematology/Oncology
Platelet Disorders

Coagulopathies, Hematology/Oncology, Platelet Disorders.

PubMed Articles

Purification and characterization of a thrombin-like enzyme isolated from Vipera lebetina venom: its interaction with platelet receptor.
Blood Coagul Fibrinolysis 2019.
Reduced multidrug resistance-associated protein 2 in ticlopidine-induced cholestatic liver injury.
Dig Liver Dis 2019.
View More

Results provided by: PubMed

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Latest RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards and Cover

  • Personae (Cover Photo)
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×